Treatment with b-AP15 to Inhibit UCHL5 and USP14 Deubiquitinating Activity and Enhance p27 and Cyclin E1 for Tumors...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• TP53 protein loss or mutation occurs in approximately 50% of human cancers.
• Targeting mutant p53 repair or Mdm2-induced degradation presents potential clinical strategies.
• The 19S proteasome plays a role in protein degradation pathways relevant to cancer.

Purpose of the Study:

• To investigate the anti-cancer effects of the USP14 and UCH37 inhibitor b-AP15.
• To determine if inhibiting 19S proteasome deubiquitinase activity can restore p53 protein levels.
• To evaluate the therapeutic potential of b-AP15 in p53-deficient cancer models.

Main Methods:

• Utilized p53 knockout mice to assess anti-cancer effects.
• Administered b-AP15, an inhibitor of UCHL5 and USP14 deubiquitinating activity.
• Analyzed gene and protein expression changes, including COPS5, AP-1, E2F1, p27, and Cyclin E1.

Main Results:

• UCHL5, USP14, and COPS5 were upregulated in p53-related tumors, correlating with shorter patient survival.
• b-AP15 treatment induced tumor regression and prolonged survival in mice.
• b-AP15 treatment led to downregulation of COPS5, AP-1, and E2F1, and upregulation of p27 and Cyclin E1.

Conclusions:

• Inhibition of UCHL5 and USP14 deubiquitinating activity in the 19S proteasome offers a novel therapeutic approach.
• This strategy may be effective in preventing tumor progression in cases of p53 deficiency.
• Targeting proteasome deubiquitinating enzymes represents a promising avenue for cancer therapy.